Latest Coronary stent Stories

Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition(TM) Drug Eluting Stent

2012-08-20 02:29:13

ABBOTT PARK, Ill., Aug. 20, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the XIENCE Xpedition(TM) Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment of coronary artery disease. The company is launching the product immediately in CE Mark countries. XIENCE Xpedition features a new stent delivery system designed to optimize acute performance, particularly in challenging coronary anatomies. XIENCE Xpedition is supported by the...

Abbott's Omnilink Elite® Vascular Balloon-Expandable Stent System Receives FDA Approval for Treatment of Iliac Artery Disease

2012-08-07 02:29:22

ABBOTT PARK, Ill., Aug. 7, 2012 /PRNewswire/ -- Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the Omnilink Elite(®) Vascular Balloon-Expandable Stent System for the treatment of iliac artery disease, a form of peripheral artery disease (PAD) that affects the lower extremities. Iliac artery disease can progress to where patients experience chronic pain and reduced ability to walk, potentially leading to permanent disability. The FDA approval...

Biosensors Reports Strong Sales and Profitability in the First Quarter of Fiscal Year 2013

2012-07-25 06:25:18

SINGAPORE, July 25, 2012 /PRNewswire-Asia/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its first fiscal quarter ended 30 June 2012 ("Q1 FY13"). Q1 FY13 Highlights: Total revenue of US$86.3 million, representing 51% year-on-year growth Interventional Cardiology Products ("IVP") sales, largely...

Biodegradable Stents Will Soon Become Commercially Available - A Dream Come True, According to Latest Market Research by RI Technologies

2012-07-17 23:00:03

RI Technologies' (http://www.researchimpact.com) exclusive market research update gives an insight into Global Stents and Biodegradable Stents market. The market is divided by Application into Coronary Arterial Stents, Peripheral Arterial Stents and Other; and by Biodegradable Material into Polymer and Metal. Hyderabad, AP (PRWEB) July 17, 2012 Global Biodegradable Stents market is projected to grow at a CAGR of about 70% through the analysis period 2015-2020. With research trials...

InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York

2012-07-05 02:24:16

TEL AVIV, Israel, July 5, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, announced today that Craig Shore, Chief Financial Officer, will present at the 7th Annual JMP Securities Healthcare Conference on July 12th in New York City. Presentation Details...

OrbusNeich's Genous(TM) Stent Is Safe and Effective in Patients Who Discontinue Dual Antiplatelet Therapy (DAPT) Within 15 Days of Stent Placement

2012-06-21 02:26:56

HONG KONG, June 21, 2012 /PRNewswire/ -- New clinical data published in the International Journal of Cardiology supports that OrbusNeich's Genous Stent is safe and effective in patients who discontinue DAPT within 15 days of stent placement. Specifically, no differences in rates of stent thrombosis (ST) and other clinical outcomes were observed between patients who discontinued DAPT prior to and after 15 days, according to the results of ARGENTO, a consecutive, prospective study in...

InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York

2012-06-15 02:25:44

TEL AVIV, Israel, June 15, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, announced today that Craig Shore, Chief Financial Officer, will present at the Marcum MicroCap Conference on June 20th in New York City. The event is hosted by Marcum LLP, one of the top ten...

ResearchMoz: Global Bare Metal Stents Market and Medical Imaging Equipment Market 2011-2015 - Market Research Report

2012-06-11 02:25:52

ALBANY, New York, June 11, 2012 /PRNewswire/ -- New Reports Added in ResearchMoz Reports Database Global Bare Metal Stents Market 2011-2015 [http://www.researchmoz.com/global-bare-metal-stents-market-2011-2015-report.html ] Global Medical Imaging Equipment Market 2011-2015 [http://www.researchmoz.com/global-medical-imaging-equipment-market-2011-2015-report.html ] Bare Metal Stents Market TechNavio's analysts forecast the Global Bare Metal Stents...

Asher Holzer Retires as President of InspireMD

2012-06-05 02:28:10

TEL AVIV, Israel, June 5, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, announced that Asher Holzer, Ph.D., president and co-founder of the Company, is retiring as president of the Company. Dr. Holzer will remain a director of InspireMD and will also provide the Company with...

Boston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS Element(TM) Plus Platinum Chromium Stent System

2012-06-04 02:26:24

NATICK, Mass., June 4, 2012 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has provided Boston Scientific Corporation (NYSE: BSX) regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element((TM)) Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug...